<DOC>
	<DOCNO>NCT00389428</DOCNO>
	<brief_summary>The primary objective study determine recommend dose CPX-351 use phase 2 efficacy study patient leukemia . Secondarily , study ass safety , serious adverse effect body handle CPX-351 . Preliminary evidence antitumor activity also determine .</brief_summary>
	<brief_title>Multicenter Study CPX-351 ( Cytarabine : Daunorubicin ) Liposome Injection Patients With Advanced Hematologic Cancer .</brief_title>
	<detailed_description>CPX-351 liposomal formulation fix combination antineoplastic drug cytarabine daunorubicin . The two drug present inside liposome 5:1 molar ratio . The development CPX-351 ( cytarabine : daunorubicin ) Liposome Injection base 1 ) define synergistic ratio two active moiety , cytarabine daunorubicin , use cell-based screening assay 2 ) design liposomal drug carrier maintain ratio intravenous administration . CPX-351 find active vivo model cancer combination conventional cytarabine daunorubicin . Both cytarabine daunorubicin active chemotherapeutic agent , approve clinical use United States treatment hematological neoplasm . CPX-351 develop hypothesis superior currently use regimen cytarabine daunorubicin treatment acute leukemia . This phase I study determine dose carry forward phase II trial .</detailed_description>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Ability understand voluntarily sign informed consent form Age &gt; 18 year time signing informed consent form Pathological confirmation leukemia myelodysplastic syndrome . AML accord WHO criteria ; except corebinding factor AMLs ( ( 8 ; 21 ) , inv ( 16 ) ( 16 ; 16 ) ) APL ALL MDS Patients AML include follow : Patients 2nd great relapse Patients first relapse initial CR duration last &lt; 6 month Patients first relapse refractory induction therapy Patients primary refractory AML Patients ALL include follow Patients Tcell ALL refractory relapse follow nelarabine Patients ALL refractory relapse . Patients MDS include follow : The subset RAEB2 patient &gt; 10 % blast least 1 prior therapy include hypomethylating agent . Previously untreated chemotherapy induce AML Eastern Cooperative Oncology Group ( ECOG ) performance status score 0,1 2 Able adhere study visit schedule protocol requirement Life expectancy least 12 week Laboratory value fulfil follow : Serum creatinine &lt; 1.5 mg/dL Serum total bilirubin &lt; 1.5 mg/dL Serum alanine aminotransferase aspartate aminotransferase &lt; 150 IU/liter Note : If elevate liver enzymes related disease ; contact medical monitor discus . Cardiac ejection fraction &gt; 50 % MUGA scan echocardiography All men woman must agree practice effective contraception study period otherwise document infertile . Any serious medical condition , laboratory abnormality psychiatric illness would prevent patient signing informed consent form Chemotherapy investigational anticancer therapeutic drug two week prior study entry ; event rapidly proliferative disease , however , use hydroxyurea permit 24 hour study entry Clinical evidence active CNS leukemic involvement Pregnant lactate woman Clinically significant cardiac disease ( New York Heart Association Class III IV ) Severe debilitate pulmonary disease Active uncontrolled infection . Patients infection active treatment antibiotic whose infection control may enter study Current evidence invasive fungal infection ( blood tissue culture ) ; HIV hepatitis C infection Hypersensitivity cytarabine , daunorubicin liposomal product History Wilson 's disease copperrelated disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Malignancies , hematologic</keyword>
	<keyword>Hematopoietic malignancy</keyword>
</DOC>